Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: succinic acid; sodium hydroxide; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose monohydrate - dbl™ oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. · treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin should not be administered to patients with a history of known allergy to oxaliplatin or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. women of childbeari

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin injection, usp used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin injection, usp should not be administered to patients with a history of known allergy to oxaliplatin injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin injection, usp may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection, usp in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - oxaliplatin, quantity: 50 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; tartaric acid - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - oxaliplatin -